Ann: ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order, page-36

Here is some of that secret wording

ArtemiCTM Rescue in its form of a food supplement, the product has now also undertaken a name change to CimetrATM.

Importantly in this respect, CimetrATM encapsulates Graft Polymer Limited’s GraftBio™ SNEDDS technology (SelfNano Emulsifying Drug Delivery System)


This is also AMC not MGC!!!!!!!!!!!!!!!!! AMC are the ones that did it. Pumping example


MGC Pharma's ArtemiC™ proprietary clinically tested COVID 19 treatment, which uses the Company's GraftBio® divisions drug delivery systems, has been listed as an over-the-counter ('OTC') drug on the US Food and Drug Administration's National Drug Code Database ('NDC'), facilitated by MGC Pharma's supply and US based distribution partner, AMC Pharma, LLC ('AMC').


^ while they say clinically tested, on the FDA sides its very much an unapproved drug and just OTC due to it having the following

OTC - ACTIVE INGREDIENTCurcuma Longa Extract, Boswellia SerrataExtract, Antioxidant Artemisinin,Vitamin C (L-Ascorbic Acid)

its a dietary supplement.

https://ndclist.com/ndc/83278-001



Here is an example of MXC paying for something and doing the "hard work with MXC cash/trials" however MXC don't own the IP. given that roby is also the same person in both companies, the "findings" are then taken back to Graft Poly who then has both the "findings and results" and the IP.



MGC Pharma, which uses Graft Polymer's drug delivery platforms in relation to MGC Pharma's CimetrA™ and CannEpil-IL™ products, confirmed that it has undertaken studies relating to the application of a base formulation nano delivery system, founded on the Company's GraftBio IP, to improve the bioavailability of the active compounds using a non-invasive drug administration process. The study examined the toxicity of the base emulation to confirm its safety profile for potential use in future clinical research. Victor Bolduev, CEO, commented: "This important work being conducted by MGC Pharma, which is supported by Graft Polymer's GraftBio IP, is a real-world example of the enormous value of the research that we are undertaking. Treating fatal cancerous brain tumours through the application of naturally derived cannabinoid products would be the definition of life-changing for so many people, and I am proud that Graft Polymer is such a critical partner in this effort."